ReachRxResearch
Home
Research
Sign Up
Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence
Back to Research Hub
  1. Home
  2. Research Hub
  3. Psilocybin for anhedonia in unipolar and…

Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence

Journal of Psychiatric Research·October 19Open Access
PsychiatryLimited evidenceAnhedoniaBipolar DepressionMajor Depressive DisorderSystematic ReviewPsychedelic-Assisted PsychotherapyAdultPsilocybin

Summary

View source

What was studied

This systematic review examined whether psilocybin improves anhedonia in unipolar (MDD) and bipolar depression, synthesizing 6 clinical and 6 preclinical (animal) studies identified through a February 2026 PubMed and Ovid database search.

Key findings

Across all 6 clinical studies, anhedonia consistently decreased after psilocybin-assisted psychotherapy (measured by SHAPS or MADRS anhedonia factor); 2 RCTs (pooled n=274) showed greater anhedonia improvement vs. control or comparator. Animal studies also showed improved reward sensitivity and motivation after psilocybin.

Study limitations

Only 12 total studies were included (6 clinical, 6 animal), with small clinical sample sizes; anhedonia measurement varied widely across studies, and most clinical studies captured only consummatory pleasure rather than anticipatory or motivational dimensions.

Clinical implications

Psilocybin-assisted psychotherapy shows early promise for reducing anhedonia in depression, but clinicians should view this as preliminary evidence requiring larger, well-controlled trials with standardized, comprehensive anhedonia measures before changing practice.

Caveats

  • Bipolar depression was included in the scope but appears underrepresented; findings may be driven predominantly by MDD populations
  • Most clinical studies measured only consummatory pleasure, potentially underestimating or mischaracterizing the full scope of anhedonia improvement
  • Preclinical animal findings may not directly translate to human anhedonia; caution is warranted in extrapolating those results to clinical settings
Show all 4
  • The pooled RCT sample (n=274) represents only 2 trials; the remaining 4 clinical studies were likely uncontrolled, limiting causal inference

Related Questions

Explore related topics

What is the mechanism by which psilocybin improves reward processing and anhedonia in depression?How does psilocybin compare to ketamine for treating anhedonia in treatment-resistant depression?What standardized tools are recommended for measuring both consummatory and anticipatory anhedonia in clinical trials?

Publication Details

Year
2026
Journal
Journal of Psychiatric Research
Sample Size
n=274
Source
View article
Keep scrolling
More content below.
Up Next